Increased Susceptibility to Endotoxin Shock in Complement C3- and C4-Deficient Mice Is Corrected by C1 Inhibitor Replacement

Journal of Immunology

Volumn 159, Issue 2, 1997, Pages 976-982

  Fischer, Michael B ^a   Prodeus, Andrey P ^a   Nicholson Weller, Anne ^a,c   Ma, Minghe ^a   Murrow, Jonathan ^a   Reid, Russell R ^a   Warren, Henry B ^d   Lage, Arthur L ^a,d   Moore Jr , Francis D ^a   Rosen, Fred S ^a,b   Carroll, Michael C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTER FOR BLOOD RESEARCH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Ctr Anim Rsrc and Compar Med   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ANIMAL; ARTICLE; DISEASE PREDISPOSITION; GENETICS; IMMUNOLOGY; MOUSE; MOUSE MUTANT; SEPTIC SHOCK;

ANIMALS; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C3; COMPLEMENT C4; DISEASE SUSCEPTIBILITY; MICE; MICE, MUTANT STRAINS; SHOCK, SEPTIC;

EID: 0031570885     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parrillo, J. E., M. M. Parker, C. Natanson, A. F. Suffredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. NIH conference: septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction and therapy. Ann. Intern. Med. 113:227.
2. Natanson, C., W. D. Hoffman, A. F. Suffredini, P. Q. Eichacker, and R. L. Danner. 1994. NIH conference: selected treatment strategies for septic shock based on proposes mechanisms of pathogenesis. Ann. Intern. Med. 120:771.
3. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457.
4. Wichterman, K. A., A. E. Baue, and I. H. Chaudry. 1980. Sepsis and septic shock: a review of laboratory models and a proposal. J. Surg. Res. 29:189.
5. Bick, R. L. 1996. Disseminated intravascular coagulation: objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin. Thromb. Hemost. 22:69.
6. May, J. E., M. A. Kane, and M. M. Frank. 1972. Host defense against bacterial endotoxemia-contribution of the early and late components of complement to detoxification. J. Immunol. 109:893.
7. Quezado, Z. M. N., W. D. Hoffman, J. A. Winkelstein, I. Yatsiv, C. A. Koev, L. C. Cork, R. J. Elin, P. Q. Eichacker, and C. Natanson. 1994. The third component of complement protects against Escherichia coli endotoxin-induced shock and multiple organ failure. J. Exp. Med. 179:569.
8. Smedegard, G., L. Cui, and T. E. Hugli. 1989. Endotoxin-induced shock in the rat: a role for C5a. Am. J. Pathol. 135:489.
9. Stevens, J. H., P. O'Hanley, J. M. Shapiro, F. G. Mihm, P. S. Satoh, J. A. Collins, and T. A. Raffin. 1986. Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J. Clin. Invest. 77:1812.
10. Wessels, M. R., P. Butko, M. Ma, H. B. Warren, A. L. Lage, and M. C. Carroll. 1995. Studies of group B streptococcal infection in mice deficient in complement C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. USA 92:11490.
11. Fischer, M. B., M. Ma, S. Goerg, X. Zhou, J. Xia, O. Finco, G. Kelsoe, R. G. Howard, T. L. Rothstein, E. Kremmer, F. S. Rosen, and M. C. Carroll. 1996. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 157:549.
12. MacMicking, J. D., C. Nathan, G. Hom, N. Chartrain, D. S. Fletcher, M. Trumbauer, S. Stevens, Q. Xie, and J. S. Mudgett. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81:641.
13. Davis, A. E., K. S. Aulak, K. Zahedi, J. J. Bissler, and R. A. Harrison. 1993. C1-Inhibitor. Methods Enzymol. 223:97.
14. Wright, S. D. 1995. CD14 and innate recognition of bacteria. J. Immunol. 156:7.
15. Wei, X. P., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408.
16. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, K. L. Rodman, J. Salfeld, E. Towne, D. Tracey, S. Wardwell, F. Y. Wei, W. Wong, R. Kamen, and T. Seshadri. 1995. Mice deficient in IL-1β-converting enzyme are deficient in production of mature IL-1β and resistant to endotoxic shock. Cell 80:401.
17. Morrison, D. C., and C. G. Cochrane. 1974. Direct evidence for Hageman factor (factor XII) activation by bacterial lipopolysaccharides (endotoxins). J. Exp. Med. 140:797.
18. Gregory, S. A., J. H. Morrissey, and T. S. Edgington. 1989. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol. Cell. Biol. 9:2752.
19. Colucci, M., G. Balconi, R. Lorenzet, A. Pietra, and D. Locati. 1983. Cultured human endothelial cells generate tissue factor response to endotoxin. J. Clin. Invest. 71:1983.
20. Nuijens, J. H., A. J. M. Eerenberg-Belmer, C. C. M. Huijbregts, W. O. Schreuder, R. J. F. Felt-Bersma, J. J. Abbink, L. G. Thijs, and C E. Hack. 1989. Proleolytic inactivation of plasma C1-inhibitor in sepsis. J. Clin. Invest. 84:443.
21. Wuillemin, W. A., M. Minnema, J. C. M. Meijers, D. Roem, A. J. M. Eerenberg, J. H. Nuijens, H. T. Cate, and C. E. Hack. 1995. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 85:1517.
22. Forbes, C. D., J. Pensky, and O. D. Ratnoff. 1970. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified C1-inactivator. J. Lab. Clin. Med. 76:809.
23. Johnson, K. J., and P. A. Ward. 1972. The requirement for serum complement in the detoxification of bacterial endotoxin. J. Immunol. 108:611.
24. Johnson, K. J., and P. A. Ward. 1971. Protective function of C6 in rabbits treated with bacterial endotoxin. J. Immunol. 106:1125.
25. Kahn, W. N., F. W. Alt, R. M. Gerstein, B. A. Maltnn, I. Larsson, G. Rathbun, L. Davidson, S. Mueller, A. B. Kantor, L. A. Herzenberg, F. S. Rosen, and P. Sideras. 1995. Defective B cell development and function in btk-deficient mice. Immunity 3:283.
26. Reid, R. R., A. P. Prodeus, W. Khan, T. Hsu, F. S. Rosen, and M. C. Carroll. 1997. Endotoxin shock in antibody-deficient mice: unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J. Immunol. In press this issue.
27. Reid, K. B. M., and R. R. Porter. 1981. The proteolytic activation system of complement. Annu. Rev. Biochem. 50:433.
28. Fearon, D. T., and W. W. Wong. 1983. Complement ligand-receptor interactions that mediate biological responses. Annu. Rev. Immunol. 1:243.
29. Quastel, M., R. Harrison, M. Cicardi, C. A. Alper, and F. S. Rosen. 1983. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J. Clin. Invest. 71:1041.
30. Donaldson, V. H. 1993. C1-inhibitor and its genetic alterations in hereditary angioneurotic edema. Int. Rev. Immunol. 10:1.
31. Waytes, A. T., F. S. Rosen, and M. M. Frank. 1996. Treatment of hereditary angioedema with a vapor-heated C1 Inhibitor concentrate. N. Engl. J. Med. 334: 1630.
32. Hack, C. E., A. C. Ogilvie, B. Eisele, A. J. Eerenberg, J. Wagstaff, and L. G. Thijs. 1993. Ci-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med. 19(Suppl 1):S19.
33. Mayer, M. M. 1961. Complement and complement fixation. In E. A. Kahat and M. M. Mayer. Experimental Immunochemistry, 2nd Ed. Charles C. Thomas, Springfield, IL, p. 133.